Hims And Hers Will Undercut Wegovy Pill With $49 Copy—Novo Stock Shudders
Online pharmaceutical retailer Hims and Hers announced Thursday it will release a much cheaper, compounded version of the Wegovy weight loss pill just over half a year after Novo Nordisk caused its stock to collapse by terminating their distribution agreement out of concern for its mass-compounding activities.
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $26.44, indicating a -2.4% shift from the previous trading day.
Hims & Hers: A Platform Strategy Pivot Driving Long-Term Value
While the market fixates on short-term product cycles, Hims & Hers (HIMS) is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. The introduction of "Labs" creates the data layer for continuous health optimization, deepening engagement and enabling increasingly precise, personalized care over time. Scale achieved from making healthcare accessible to millions helps the company drive down unit costs, lower prices, expand adoption, and create a self-reinforcing flywheel of growing reach, engagement, and long-term platform value.
Hims & Hers: It's Time To Get Aggressive
Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber growth underpin a compelling long-term growth thesis despite recent profit volatility. Significant investments in global expansion, new product lines, and vertical integration are expected to drive future margin expansion and revenue acceleration.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reached $29.68 at the closing of the latest trading day, reflecting a -1.98% change compared to its last close.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Scales Platform-Led Digital Healthcare Access and Care
HIMS expands its tech-driven care platform with new diagnostics, AI tools and specialty treatments for personalized health.
Hims & Hers Health: The Reset Nobody Expected
Revenue grew nearly 50% year over year in Q3 2025 to ~$600 million, with ARPU rising and free cash flow reaching $79 million. Gross margin declined to ~74% from high-70s levels due to GLP-1 shipping cadence changes, price cuts, and facility expansion inefficiencies. Operating cash flow approached $150 million in the quarter, with over $1 billion in cash and investments supporting reinvestment and buybacks.
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling?
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Hims & Hers Expands Platform-Led Access to Digital Healthcare
HIMS leverages a software-driven platform to scale personalized digital care across new health categories and markets.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
